Efficacy and safety of telitacicept in the treatment of IgA nephropathy: a single-center, real-world study.

ABSTRACT:

Aim

To evaluate the efficacy and safety of Telitacicept in patients with IgA nephropathy. Telitacicept is a fusion protein that inhibits B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby modulating B-cell activation and survival.

Methods

A single-center, retrospective analysis of data from 24 patients with IgA nephropathy who received telitacicept 160 mg per week, with a minimum continuous treatment of 12 weeks, from August 2022 to January 2024. Patients were categorized by treatment regimen: telitacicept monotherapy (Group A, n = 8), telitacicept combined with low-dose corticosteroids (prednisone 0.3-0.5 mg/kg/day) (Group B, n = 8), and telitacicept combined with full-dose corticosteroids or corticosteroids plus other immunosuppressants (G

SUBMITTER: Tao L 

PROVIDER: S-EPMC12515874 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature